HHS · Notice · Rel 100 (Federal Register (major agencies))
Issuance of Priority Review Voucher; Rare Pediatric Disease Product; ISEMBYLD (apitegromab-mstn)
Other · Health / life sciences · general, public-health, fda-guidance
Source summary
The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that ISEMBYLD (apitegromab-mstn), approved September 11, 2026, manufactured by Scholar Rock, Inc., meets the criteria for a priority review voucher.
Analyst note
HHS published an official item relevant to other. Use the source link to verify scope before advising clients.
Public reaction (Reddit)
Insufficient public reaction to score sentiment.